Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

van Krieken, JH; Jung, A; Kirchner, T; Carneiro, F; Seruca, R; Bosman, FT; Quirke, P; Fléjou, JF; Plato Hansen, T; de Hertogh, G; Jares, P; Langner, C; Hoefler, G; Ligtenberg, M; Tiniakos, D; Tejpar, S; Bevilacqua, G; Ensari, A.
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
Virchows Arch. 2008; 453(5): 417-431. Doi: 10.1007/s00428-008-0665-y [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

Co-authors Med Uni Graz: Höfler Gerald; Langner Cord
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with colorectal carcinoma. However, these therapies are effective only in a subset of patients. Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies. Thus, KRAS mutation status can predict which patient may or may not benefit from anti-EGFR therapy. Although many diagnostic tools have been developed for KRAS mutation analysis, validated methods and standardized testing procedures are lacking. This poses a challenge for the optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Here we review the molecular basis of EGFR-targeted therapies and the resistance to treatment conferred by KRAS mutations. We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union.
Find related publications in this database (using NLM MeSH Indexing): Antibodies - therapeutic use; Colorectal Neoplasms - drug therapy; Europe -; Genetic Screening -; Humans -; Point Mutation - genetics; Predictive Value of Tests -; Proto-Oncogene Proteins - genetics; Quality Assurance, Health Care -; Receptor, Epidermal Growth Factor - antagonists and inhibitors; ras Proteins - genetics
Find related publications in this database (Keywords): Colorectal carcinoma; Anti-EGFR therapy; KRAS mutation testing; Practice guidelines; Quality assurance